The purpose of this study is to determine if combining a virtual diabetes self-management program (DECIDE®) with continuous glucose monitoring (CGM) is practical and well-received by adults with type 2 diabetes. Twenty participants will attend the 9-week, virtual DECIDE Self-Management Program. They will receive CGM sensors to wear during the 22-week study to track their blood sugar. Participants will complete questionnaires at three time points -- at baseline, 1 week after the DECIDE Program ends, and 3 months after the DECIDE Program ends. They will also complete a blood draw to measure hemoglobin A1C at baseline and 3 months after the intervention ends. Additionally, they will complete a brief interview after the program ends to gather insights into participants' experiences with the program. The study aims to examine whether this integrated approach will be both feasible and acceptable, potentially leading to better diabetes management and improved health outcomes.
Inclusion Criteria:
Exclusion Criteria:
evrany@northwell.edu516-600-1483
No masking
Participants will receive: 1. The 9-week, virtually delivered DECIDE Self-Management Program. 2. Continuous glucose monitoring (CGM) sensors
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations
Evaluation of a Digital Diabetes Self-Management Education and Support Program
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
Continuous Glucose Monitoring and Behavioral Change Intervention for People With Type 2 Diabetes and Diabetes Distress
Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for Type 2 Diabetes
Integrating New Skills Into Diabetes Education With CGM